PRKN and Parkinson disease: Previously, it was demonstrated that PARK2-PD fibroblasts, carrying a compound heterozygous deletional mutation of PARK2 gene (del exon2/3 and del exon 3), have lost full-length parkin protein compared to CTR2, which displayed only heterozygous deletion in exon 3.